Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells

European Journal of Pharmacology

Volumn 581, Issue 1-2, 2008, Pages 37-46

  Heusler, Peter ^a   Newman Tancredi, Adrian ^a   Loock, Timothé ^a   Cussac, Didier ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Aripiprazole; Bifeprunox; Clozapine; Dopamine D2S receptor; Internalisation; Serotonin 5 HT1A receptor

Indexed keywords

ARIPIPRAZOLE; BIFEPRUNOX; BUSPIRONE; CLOZAPINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; F 15063; GUANINE NUCLEOTIDE BINDING PROTEIN; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NEUROLEPTIC AGENT; PINDOLOL; PIPERAZINE; QUINPIROLE; SARIZOTAN; SEROTONIN 1A ANTAGONIST; SEROTONIN 5 RECEPTOR; SSR 181507; ZIPRASIDONE;

ARTICLE; COLORIMETRY; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; KIDNEY CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANTIPSYCHOTIC AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; QUINPIROLE; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2;

EID: 38549162242     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.11.046     Document Type: Article

References (53)

1. Böhm S.K., Grady E.F., and Bunnett N.W. Regulatory mechanisms that modulate signalling by G-protein-coupled receptors. Biochem. J. 322 (1997) 1-18
2. 2S receptors coupled to extracellular signal-regulated kinase. Eur. J. Pharmacol. 534 (2006) 63-70
3. 3 partial agonist. J. Pharmacol. Exp. Ther. 315 (2005) 1278-1287
4. Claustre Y., Peretti D.D., Brun P., Gueudet C., Allouard N., Alonso R., Lourdelet J., Oblin A., Damoiseau G., Francon D., Suaud-Chagny M.F., Steinberg R., Sevrin M., Schoemaker H., George P., Soubrie P., and Scatton B. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. I: Neurochemical and electrophysiological profile. Neuropsychopharmacol. 28 (2003) 2064-2076
5. 1A receptors expressed in HeLa cells. Eur. J. Pharmacol. 433 (2001) 55-62
6. 2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535 (2006) 135-144
7. 2 receptors. Eur. J. Pharmacol. 394 (2000) 47-50
8. 1A receptors. Psychopharmacol. 162 (2002) 168-177
9. 1A receptor-mediated Erk activation requires calcium/calmodulin-dependent receptor endocytosis. J. Biol. Chem. 274 (1999) 4749-4753
10. 4 partial agonist properties: II) Activity in models of positive symptoms of schizophrenia. Br. J. Pharmacol. 151 (2007) 253-265. 10.1038/sj.bjp.0707159
11. 4 partial agonist properties: III) Activity in models of cognition and negative symptoms. Br. J. Pharmacol. 151 (2007) 266-277. 10.1038/sj.bjp.0707160
12. Ferguson S.S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53 (2001) 1-24
13. Fukunaga S., Setoguchi S., Hirasawa A., and Tsujimoto G. Monitoring ligand-mediated internalization of G protein-coupled receptor as a novel pharmacological approach. Life Sci. 80 (2006) 17-23
14. 2A receptors by agonists and antagonists. Brain Res. Bull. 56 (2001) 441-451
15. 2 dopamine receptors. Br. J. Pharmacol. 121 (1997) 731-736
16. 1A receptor function in brain following agonist or antidepressant administration. Life Sci. 72 (2003) 1665-1682
17. 2L receptors coupled to GIRK potassium channels. Neuropharmacol. 52 (2007) 1106-1113
18. Holst B., Holliday N.D., Bach A., Elling C.E., Cox H.M., and Schwartz T.W. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 279 (2004) 53806-53817
19. 2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. Eur. J. Biochem. 260 (1999) 112-119
20. 2 receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 49 (1996) 560-566
21. 2 receptors. Eur. J Biochem. 263 (1999) 596-602
22. 1A receptor. Eur. J. Pharmacol. 441 (2002) 137-140
23. Kallal L., and Benovic J.L. Fluorescence microscopy techniques for the study of G protein-coupled receptor trafficking. Methods Enzymol. 343 (2002) 492-506
24. 2 receptors. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1081-1090
25. Khawaja X.Z., Smith D.L., Nawoschik S.P., Zhang J., Dunlop J., Dilks D.W., Olsen M., and Schechter L.E. WAY-100635 antagonist-induced plasticity of 5-HT receptors: regulatory differences between a stable cell line and an in vivo native system. J. Neurochem. 98 (2006) 134-145
26. 3 receptors by G protein-coupled receptor kinases and β-arrestins. J. Biol. Chem. 276 (2001) 37409-37414
27. 2 receptor. Mol. Endocrinol. 18 (2004) 640-652
28. Leterrier C., Bonnard D., Carrel D., Rossier J., and Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J. Biol. Chem. 279 (2004) 36013-36021
29. 1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J. Pharmacol. Exp. Ther. 286 (1998) 345-353
30. Li J.G., Luo L.Y., Krupnick J.G., Benovic J.L., and Liu-Chen L.Y. U50,488H-induced internalization of the human κ opioid receptor involves a β-arrestin- and dynamin-dependent mechanism. κ receptor internalization is not required for mitogen-activated protein kinase activation. J. Biol. Chem. 274 (1999) 12087-12094
31. 1A receptor agonist potential antipsychotic drug. Neuropsychopharmacol. 32 (2007) 78-94
32. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
33. 2-adrenergic receptor sequestration: intracellular complement of β-adrenergic receptor kinase and β-arrestin determine kinetics of internalisation. Mol. Pharmacol. 51 (1997) 800-808
34. 1A) receptors. Neuropsychopharmacol. 5 (1998) 395-398
35. 35S]GTPγS binding study. Eur. J. Pharmacol. 21 (1998) 245-256
36. 3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur. J. Pharmacol. 428 (2001) 177-184
37. 1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 341-356
38. 4 partial agonist properties: I) in vitro receptor affinity and efficacy profile. Br. J. Pharmacol. 151 (2007) 237-252. 10.1038/sj.bjp.0707158
39. 1A ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacol. (Berl.) 144 (1999) 20-29
40. Pfeiffer M., Kirscht S., Stumm R., Koch T., Wu D., Laugsch M., Schroder H., Hollt V., and Schulz S. Heterodimerization of substance P and μ-opioid receptors regulates receptor trafficking and resensitization. J. Biol. Chem. 278 (2003) 51630-51637
41. Reiter E., and Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 17 (2006) 159-165
42. 1 receptor agonists. Mol. Pharmacol. 68 (2005) 1039-1048
43. Szekeres P.G., Koenig J.A., and Edwardson J.M. The relationship between agonist intrinsic activity and the rate of endocytosis of muscarinic receptors in a human neuroblastoma cell line. Mol. Pharmacol. 53 (1998) 759-765
44. Tsai S.-J. Dopamine receptor downregulation: an alternative strategy for schizophrenia treatment. Med. Hypotheses 63 (2004) 1047-1050
45. 1 receptor-mediated signaling pathways. Neuropsychopharmacol. 32 (2007) 67-77
46. Wadenberg M.L. Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci. Biobehav. Rev. 20 (1996) 325-339
47. Whistler J.L., and von Zastrow M. Morphine-activated opioid receptors elude desensitization by β-arrestin. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9914-9919
48. Whistler J.L., Chuang H.H., Chu P., Jan L.Y., and von Zastrow M. Functional dissociation of μ-opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23 (1999) 737-746
49. Willins D.L., Berry S.A., Alsayegh L., Backstrom J.R., Sanders-Bush E., Friedman L., and Roth B.L. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neurosci. 91 (1999) 599-606
50. Wolf W. DU-127090 Solvay/H Lundbeck. Curr. Opin. Investig. Drugs 4 (2003) 72-76
51. 2A receptor blockade. CNS Neurol. Disord. Drug Targets 5 (2006) 445-452
52. Zaki P.A., Keith Jr. D.E., Thomas J.B., Carroll F.I., and Evans C.J. Agonist-, antagonist-, and inverse agonist-regulated trafficking of the δ-opioid receptor correlates with, but does not require, G protein activation. J. Pharmacol. Exp. Ther. 298 (2001) 1015-1020
53. Zhang J., Fergusson S.S.G., Barak L.S., Bodduluri S.R., Laporte S.A., Law P.Y., and Caron M.G. Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7157-7162